Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C

Hepatology

Volumn 63, Issue 2, 2016, Pages 428-436

  Chidi, Alexis P ^a,b   Rogal, Shari ^a,b   Bryce, Cindy L ^a,c   Fine, Michael J ^a,b   Good, Chester B ^a,b,d   Myaskovsky, Larissa ^a,b   Rustgi, Vinod K ^a   Tsung, Allan ^a   Smith, Kenneth J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; PEGYLATED INTERFERON PLUS RIBAVIRIN PLUS SOFOSBUVIR; RIBAVIRIN; SIMEPREVIR; SIMEPREVIR PLUS SOFOSBUVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; DRUG COMBINATION; FLUORENE DERIVATIVE; LEDIPASVIR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; HELP SEEKING BEHAVIOR; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT RESPONSE; UNITED STATES; VETERAN; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; HEPATITIS C, CHRONIC; MIDDLE AGED; VETERANS HEALTH;

AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SOFOSBUVIR; UNITED STATES; VETERANS HEALTH;

EID: 84956811078     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28327     Document Type: Article

References (57)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
2. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31:1090-1101.
3. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the U.S. Gastroenterology 2015;148:547-555.
4. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-338.
5. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009;50:387-392.
6. Dieperink E, Pocha C, Thuras P, Knott A, Colton S, Ho SB. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci 2014;59:872-880.
7. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
8. Cawthorne CH, Rudat KR, Burton MS, Brown KE, Luxon BA, Janney CG, Fimmel CJ. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002;97:149-155.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
10. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
11. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
12. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-1765.
13. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014;60:530-537.
14. Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188). J Hepatol 2014;61:7-14.
15. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-1603.
16. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-1992.
17. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.
18. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
19. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
20. Canary LA, Klevens RM, Holmberg SD. Limited access to new hepatitis C virus treatment under state Medicaid programs limited access to new HCV treatment. Ann Intern Med 2015;163:226-228.
21. Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder JL, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 2005;41:88-96.
22. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-36.
23. Kim WR, Stock PG, Smith JM, Heimbach JK, Skeans MA, Edwards EB, et al. OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant 2013;13 Suppl 1:73-102.
24. US Department of Veterans Affairs. Hepatitis C treatment: request for choice program flexibility to address $500 million shortfall in FY 2015 (July 14, 2015). Available at: http://www.natap.org/2015/HCV/hepatitis_c_treatment_summary.pdf. Accessed on October 30, 2015.
25. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012;54:1259-1271.
26. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014;60:741-747.
27. Younossi ZM, Stepanova M, Nader F, Jacobson IM, Gane E, Nelson D, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014;59:2161-2169.
28. Hanmer J. Predicting an SF-6D preference-based score using MCS and PCS scores from the SF-12 or SF-36. Value Health 2009;12:958-966.
29. Gold MR. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:xxiii.
30. Braithwaite RS, Meltzer DO, King JT, Jr., Leslie D, Roberts MS. What does the value of modern medicine say about the $50, 000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-356.
31. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:157-177.
32. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol 2013;11:1503-1510.
33. Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat 2013;20:847-857.
34. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014;161:170-180.
35. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-419.
36. Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol 2015;15:98.
37. The State of VA's Fiscal Year 2015 Budget: Statement of the Honorable Sloan Gibson Deputy Secretary of Veterans Affairs. In: US House of Representatives Committee on Veterans' Affairs, 114th Congress; 2015.
38. Surface Transportation and Veterans Health Care Choice Improvement Act of 2015. In: Public Law 114-41. 114th Congress, ed. United States of America; 2015.
39. U.S. Food and Drug Administration (FDA). FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. Silver Spring, MD: FDA; 2015.
40. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-521, 521.e1-6.
41. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012;56:320-325.
42. Hwang EW, Thomas IC, Cheung R, Backus LI. Implications of rapid virological response in hepatitis C therapy in the US veteran population. Aliment Pharmacol Ther 2012;35:105-115.
43. Thomas LB, Foulis PR, Mastorides SM, Djilan YA, Skinner O, Borkowski AA. Hepatitis C genotype analysis: results in a large veteran population with review of the implications for clinical practice. Ann Clin Lab Sci 2012;42:355-362.
44. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-431.
45. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54:396-405.
46. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
47. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010;32:344-355.
48. Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40:823-830.
49. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010;10:1003-1019.
50. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009;50:89-99.
51. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010;16:748-759.
52. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011;53:150-157.
53. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014;60:37-45.
54. Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant 2010;10:961-972.
55. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005;100:643-651.
56. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100-2107.
57. Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, et al. Turquoise-III: safety and efficacy of 12-week ribavirin-free treatment for patients with HCV genotype 1b and cirrhosis. J Viral Hepat 2015;22:134-135.